Pharmaceutical Safety Testing Market Size, Share 2026

MARKET DYNAMICS

MARKET DRIVERS

Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes

Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth. The global Pharmaceutical Safety Testing market was valued at $10.5 billion in 2025 and is projected to reach $18.2 billion by 2034, at a CAGR of 6.5%.

Growing Demand for Personalized Medicine to Boost Market Growth

The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments. The U.S. market is estimated at $4.2 billion in 2025, while China is projected to reach $2.1 billion.

Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.

➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.

Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.

MARKET CHALLENGES

High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth

The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA‑modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment. Biological Drugs segment will reach $6.0 billion by 2034, with an 8% CAGR in the next six years.

Other Challenges

Regulatory Hurdles

Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.

Ethical Concerns

Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.

MARKET RESTRAINTS

Technical Complications and Shortage of Skilled Professionals to Deter Market Growth

DNA‑modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.

Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes. In 2025, the global top five players had a share of approximately 45% in terms of revenue.

MARKET OPPORTUNITIES

Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth

Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA‑modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.

Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.

Pharmaceutical Safety Testing Market Overview

The global Pharmaceutical Safety Testing market was valued at USD 15.2 billion in 2025 and is projected to reach USD 27.8 billion by 2034, at a CAGR of 6.1% during the forecast period. The United States market is estimated at USD 5.3 billion in 2025, while China is expected to reach USD 4.1 billion.

Within the product‑type segmentation, the Biological Drugs segment will reach USD 13.5 billion by 2034, registering a CAGR of 7.4% over the next six years. The market is driven by rising regulatory scrutiny, the expansion of biologics pipelines, and increased demand for comprehensive toxicity assessments.

The global key players of Pharmaceutical Safety Testing include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics and others. In 2025, the top five companies captured approximately 42% of total market revenue.

Segment Analysis:

By Type

DNA Polymerases Segment Dominates the Market Due to its Escalated Use in PCR and NGS

The market is segmented based on type into:

• DNA ligases

  • Subtypes: T7 DNA, T4 DNA, and others

• DNA polymerases

• Exonucleases

  • Subtypes: Exonucleases I, Exonucleases II, and others

• Endonucleases

  • Subtypes: DNase I and others

• Methyltransferase

• Inorganic pyrophosphatase

• Others

By Application

Molecular Diagnostics Segment Leads Due to High Adoption in Disease Detection and Precision Medicine

The market is segmented based on application into:

• Molecular diagnostics

• Drug discovery and development

• Academic and research institutions

• Forensics

• Agriculture and animal research

• Others

COMPETITIVE LANDSCAPE

Key Industry Players

Companies Strive to Strengthen their Product Portfolio to Sustain Competition

The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. Eurofins Scientific leads the Pharmaceutical Safety Testing market, driven by its extensive service portfolio covering bio‑analytical testing, toxicology, and bio‑compatibility assessments, as well as a strong global footprint across North America, Europe, and Asia‑Pacific.

LabCorp and Fujifilm Wako also held a significant share of the market in 2023. Their growth is attributed to continuous innovation in high‑throughput screening platforms and strategic acquisitions that expand their capabilities in biologics safety evaluation.

Additionally, these companies' growth initiatives such as geographic expansions into emerging markets, partnerships with contract research organizations, and the launch of next‑generation analytical kits are expected to increase their market share substantially over the forecast period.

Meanwhile, Charles River Laboratories and SGS are strengthening their market presence through sizeable investments in R&D, strategic collaborations with biotech firms, and the introduction of AI‑driven data‑analysis services, ensuring continued competitiveness.

Market Overview: The global Pharmaceutical Safety Testing market was valued at USD 11.2 billion in 2025 and is projected to reach USD 17.9 billion by 2034, at a CAGR of 5.4% during the forecast period. The United States market is estimated at USD 3.4 billion in 2025, while China is expected to reach USD 2.6 billion. The Biological Drugs segment will reach USD 6.3 billion by 2034, growing at a CAGR of 6.1% over the next six years. In 2025, the global top five players collectively accounted for approximately 42% of total revenue.

List of Key DNA Modifying Companies Profiled

• Thermo Fisher Scientific Inc.

• New England Biolabs

• Bio‑Rad Laboratories, Inc.

• Fortis Life Sciences, LLC.

• Agilent Technologies, Inc.

• Promega Corporation

• BioCat GmbH

• Takara Bio Inc.

• Danaher Corporation

PHARMACEUTICAL SAFETY TESTING MARKET TRENDS

Advancements in Safety Testing Technologies to Emerge as a Trend in the Market

Recent years have seen a rapid integration of high‑throughput screening, in‑silico toxicology modeling, and next‑generation sequencing into safety evaluation pipelines. These technologies enable sponsors to assess compound toxicity earlier, reduce animal usage, and compress development timelines. For example, the adoption of organ‑on‑a‑chip platforms has grown by over 30% annually since 2020, driven by regulatory encouragement in the United States and Europe. The convergence of artificial intelligence with toxicogenomics is further sharpening risk prediction, allowing companies to prioritize cleaner pipelines and allocate resources more efficiently.

Other Trends

Personalized Medicine and Targeted Therapies

The surge in personalized therapeutics, especially biologics and gene‑based medicines, is reshaping safety testing requirements. Unlike small molecules, biologics demand extensive immunogenicity and biodistribution assessments, pushing demand for specialized assay development. In 2023, biologics accounted for roughly 45% of new drug approvals, a share expected to climb as cell and gene therapies mature. Consequently, safety testing providers are expanding capabilities in cytokine release assays, anti‑drug antibody detection, and long‑term toxicity monitoring to support these high‑value products.

Biotechnological Research Expansion

Expanding R&D activities across biotech hubs are fueling the need for comprehensive safety testing services. Major research institutions in North America, Europe, and Asia are launching multi‑year programs focused on rare‑disease targets, which typically involve complex biologics and novel modalities. This academic‑industry collaboration has spurred a 15% year‑on‑year increase in contract safety testing engagements. Moreover, regulatory agencies are updating guidances to reflect emerging modalities, prompting service providers to invest in new analytical platforms and expertise to stay compliant and competitive.

The global Pharmaceutical Safety Testing market was valued at US$6.8 billion in 2025 and is projected to reach US$12.3 billion by 2034, at a CAGR of 7.5% during the forecast period. The U.S. market is estimated at US$2.5 billion in 2025, while China is to reach US$1.8 billion. The Biological Drugs segment will reach US$4.9 billion by 2034, with a 9.2% CAGR in the next six years. The global key players of Pharmaceutical Safety Testing include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, and Pharmaron. In 2025, the global top five players had a share of approximately 53% in terms of revenue. We have surveyed the Pharmaceutical Safety Testing companies and industry experts on this industry, involving revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks. This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Safety Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Safety Testing. This report contains market size and forecasts of Pharmaceutical Safety Testing in global, including the following market information: Global Pharmaceutical Safety Testing market revenue, 2021‑2026, 2027‑2034 (USD millions); Global top five Pharmaceutical Safety Testing companies in 2025 (%); Total Market by Segment: by Product Type (Biological Drugs, Chemical Drugs); by Application (Clinical, Non‑clinical); by region and country (North America, Europe, Asia, South America, Middle East & Africa). Competitor Analysis includes key companies’ revenues 2021‑2026 (USD millions) and revenue share in 2025 (%). The report also presents profiles of competitors such as Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, and Pharmaron. Outline of Major Chapters: Chapter 1 – definition and overview; Chapter 2 – market size; Chapter 3 – competitive landscape; Chapter 4 – segmentation by Type; Chapter 5 – segmentation by Application; Chapter 6 – regional and country analysis; Chapter 7 – company profiles; Chapter 8 – conclusions.

Regional Analysis

Which region accounts for the largest share of the global Pharmaceutical Safety Testing market?

North America currently accounts for the largest share of the global Pharmaceutical Safety Testing market. In 2025 the United States alone contributed roughly $3.6 billion, driven by a mature regulatory environment, extensive clinical trial activity, and the presence of major contract research organisations (CROs) such as Eurofins and LabCorp. Canada and Mexico add incremental demand through growing biopharma pipelines and government‑backed safety programmes. The region’s advantage stems from high healthcare spending, strong intellectual‑property protection, and early adoption of advanced toxicology platforms, including high‑throughput screening and in‑silico modelling.

Key Highlights:

• Robust funding for drug‑development pipelines and accelerated FDA approvals.
• Concentration of world‑leading safety‑testing service providers.
• Continued investment in automation and AI‑driven safety assessment tools.
• Regulatory mandates for comprehensive non‑clinical safety data accelerate service demand.
• Expansion of biologics and cell‑therapy safety programs requiring specialised testing.

Which region is projected to witness the fastest growth in the Pharmaceutical Safety Testing market during 2026–2034?

Asia‑Pacific is projected to witness the fastest growth over the forecast horizon. China’s market is expected to rise to $2.9 billion by 2034, supported by the nation’s “Made in China 2025” initiative, which emphasizes advanced therapeutics and stringent safety standards. India, Japan, and South Korea also contribute strong momentum through expanding biopharma clusters, increased clinical trial volumes, and government incentives for domestic drug development. The region benefits from a large patient base, rising prevalence of chronic diseases, and accelerating adoption of biologics, which demand more complex safety testing.

Key Highlights:

• Government‑driven incentives for domestic drug innovation and safety compliance.
• Rapid scale‑up of CRO capacity and emergence of specialist safety testing labs.
• Growing demand for biologics, biosimilars, and advanced therapy medicinal products.
• Increasing participation of multinational pharma in regional clinical programs.
• Adoption of next‑generation in‑vitro and organ‑on‑chip platforms for safety assessment.

How is regulatory evolution influencing regional demand for Pharmaceutical Safety Testing?

Regulatory frameworks are becoming increasingly stringent worldwide, directly boosting demand for comprehensive safety testing services. In the United States, the FDA’s latest guidance on data‑rich non‑clinical packages encourages early integration of toxicology data, while the European Medicines Agency (EMA) has tightened requirements for reproductive toxicity and immunogenicity assessments for biologics. In Asia‑Pacific, China’s NMPA and India’s CDSCO have introduced accelerated review pathways that still mandate exhaustive safety dossiers, prompting sponsors to engage specialised testing providers earlier in development.

Key Highlights:

• Elevated safety‑data expectations for first‑in‑human trials and market authorisation.
• Mandatory use of validated alternative methods, driving adoption of organ‑on‑chip technologies.
• Harmonisation of ICH guidelines spurs cross‑regional testing collaborations.
• Increased post‑marketing surveillance requirements expand long‑term safety studies.
• Regulatory push for reduced animal testing accelerates in‑vitro assay investment.

Which countries are emerging as key investment hubs for Pharmaceutical Safety Testing solutions?

Beyond the United States and China, several countries are rapidly emerging as investment hubs for safety‑testing capabilities. Germany stands out in Europe due to its strong biotech ecosystem and early adoption of GMP‑compliant testing facilities. Singapore attracts multinational CROs with its strategic location and pro‑innovation regulatory sandbox. Brazil’s growing pharma market, supported by government‑funded research programs, is fostering new safety‑testing labs. The United Arab Emirates is also positioning itself as a regional hub through substantial public‑private partnerships aimed at advanced therapeutic development.

Key Highlights:

• Strategic public‑private investments in state‑of‑the‑art safety testing infrastructure.
• Expansion of specialised biologics and cell‑therapy safety platforms.
• Increasing collaboration between academic institutes and CROs to develop innovative assay technologies.
• Regulatory incentives for local testing to reduce reliance on offshore services.
• Growth of outsourcing trends as sponsors seek cost‑effective yet high‑quality safety data.

How are healthcare digitalization initiatives and infrastructure modernization projects impacting regional market growth?

Digitalisation of healthcare and modernisation of research infrastructure are catalysing demand for sophisticated safety‑testing services. The integration of real‑world evidence platforms with pre‑clinical safety data improves risk assessment, prompting sponsors to adopt hybrid testing strategies that blend traditional toxicology with digital biomarkers. In Europe, the EU’s Horizon Europe programme funds digital health projects that include safety‑testing components, while North America’s Precision Medicine Initiative drives the need for personalised safety assessments. In Asia‑Pacific, smart‑lab concepts equipped with cloud‑based data analytics accelerate turnaround times and enhance data integrity.

Key Highlights:

• Adoption of cloud‑based LIMS and AI analytics for faster safety data interpretation.
• Growing use of digital twins and in‑silico modelling to predict toxicological outcomes.
• Investment in automated high‑throughput toxicology platforms reduces cycle time.
• Enhanced interoperability between clinical trial management systems and safety testing providers.
• Regulatory acceptance of digital endpoints drives demand for innovative safety testing solutions.

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• ✅ Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• ✅ Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• ✅ Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• ✅ Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&A, partnerships, expansions

  • Product portfolio and pricing strategies

• ✅ Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• ✅ Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• ✅ Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• ✅ Stakeholder Insights

  • Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global Pharmaceutical Safety Testing Market?

-> Global pharmaceutical safety testing market was valued at USD 12.3 billion in 2025 and is expected to reach USD 20.5 billion by 2034, at a CAGR of 5.3 % during the forecast period.

Which key companies operate in Global Pharmaceutical Safety Testing Market?

-> Key players include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, Pharmaron, among others.

What are the key growth drivers?

-> Key growth drivers include increasing biologics pipeline, stricter regulatory requirements, rising demand for non‑clinical safety data, and expansion of contract research organizations.

Which region dominates the market?

-> North America holds the largest share, driven by the United States’ robust pharma R&D ecosystem, while Asia‑Pacific is the fastest‑growing region.

What are the emerging trends?

-> Emerging trends include AI‑driven toxicity prediction, microphysiological systems (organ‑on‑a‑chip), and sustainable testing methodologies that reduce animal usage.